Search Results

Notwithstanding a long manufacturing existing products in the core plasma, recombinant and vaccine cycle (typically 9-12 months) we expect the tightness in supply platforms is driven by expanding markets and indications to alleviate throughout the rest of the calendar year.

CSL's Awards, Grants and Initiatives

Financial Year The Company's financial year ends on June 30 of each calendar year.

1 Chairman and CEO's Letter 2 CSL Calendar 2 2019 Performance 4 2019 Business performance and highlights 4 14 August Annual profi t and fi nal dividend announcement Financial highlights 5 10 September Shares traded ex-dividend 3 Our Company 6 11 September Record date for fi nal dividend Our businesses 6 Our locations 7 11 October Final dividend paid Our product portfolio 8 16 October Annual General Meeting Our research and development pipeline 9 31 December Half year ends 4 CSL Strategy 10 2020 How we create value 12 12 February Half year profi t and interim dividend 5 Powered by Innovation 14 announcement Collaboration with and funding of medical research 14 11 March Shares traded ex-dividend Investment in research and development pipeline 14 12 March Record date for interim dividend Focus on selected therapeutic areas - specialisation 15 9 April Interim dividend paid New products to market 16 30 June Year ends Clinical trials in process and new 18 19 August Annual profi t and fi nal dividend announcement Clinical trial transparency 18 10 September Shares traded ex-dividend Leveraging advanced analytics and artifi cial intelligence 19 11 September Record date for fi nal dividend Innovation across the value chain 19 9 October Final dividend paid 6 Global Reach and Impact 21 14 October Annual General Meeting Global reach and focus 21 31 December Half year ends Donor management 24 Focus on effi ciency, standardised manufacturing 24 processes and integrated supply chain Annual General Meeting Environment health and safety 25 Wednesday, 16 October 2019 at 1 p.m. Supply chain management 25 7 A Trusted Health Partner 26 New city and venue Product quality and safety 26 Value and access 27 The Westin Sydney, Grand Ballroom Public policy engagement 28 1 Martin Place Secure and reliable supply 29 Sydney NSW 2000 Pandemic and emergency response 29 Relationships with healthcare professionals 29 Share Registry regulators and patient groups Computershare Investor Services Pty Limited Responsible marketing and promotion 29 Postal Address:

CSL Calendar Annual General Meeting 2020 Key Dates 19 August Annual profi t and fi nal 2020 Annual General Meeting (AGM) of CSL Limited dividend announcement (ABN 99 051 588 348) will be held online on 10 September Shares traded ex-dividend Wednesday, 14 October 2020 at 10 am (Melbourne time).

CSL announced the 2022 Half Year Financial Results for the period ending 31st December 2021, on Wednesday, 16th February 2021 (AEDT)

CSL announced 2023 Half Year Financial Results for the period ending 31st December 2022, on Tuesday, 14th February 2023 (AEDT)

We announced our 2021 Half Year Financial Results on Thursday, 18th February 2021 (AEDT).

Joy Linton is the Chief Financial Officer (CFO) of CSL Limited. Read Joy's biography.

Ms Carolyn Hewson is a Director of CSL Limited